Access Program Lenz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm,' announced today that lenzilumab is now

United statesUnited kingdomRob foxTimothye morrisAsia pacificPete beldenAndrea aroldiServices divisionAccess program lenzCorporate developmentClinigen groupEuropean unionHumanigen incConsilium strategic communicationsManaged access programExecutive vice president services division